Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure

Journal of Clinical Oncology

Volumn 31, Issue 6, 2013, Pages

  Westgeest, Hans M ^a   Van Erp, Nielka P ^b   Honeywell, Richard J ^a   Hoekstra, Ronald ^c   Peters, Godefridus J ^a   Verheul, Henk M W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TWENTEBORG HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB;

AGED; ANOREXIA; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; HEPATITIS; HUMAN; KIDNEY CARCINOMA; LIVER TOXICITY; MALAISE; MALE; NAUSEA; PANCYTOPENIA; PRIORITY JOURNAL; SIDE EFFECT; SPLEEN METASTASIS;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG-INDUCED LIVER INJURY; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; TREATMENT OUTCOME;

EID: 84875758191     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.6485     Document Type: Article

References (21)

1. Honeywell R, Yarzadah K, Giovannetti E, et al: Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:1059-1068, 2010
2. Di Lorenzo G, Buonerba C, Biglietto M, et al: The therapy of kidney cancer with biomolecular drugs. Cancer Treat Rev 36:S16-S20, 2010 (suppl 3)
3. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
4. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006
5. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
6. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
7. Pfizer: Summary of product characteristics: Sutent (sunitinib). http://www- .medicines.org.uk/emc/medicine/18531/SPC
8. van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692-706, 2009
9. Shukla S, Robey RW, Bates SE, et al: Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATPbinding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37:359-365, 2009
10. Keskitalo JE, Zolk O, Fromm MF, et al: ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197-203, 2009
11. Mizuno T, Terada T, Kamba T, et al: ABCG2 421CA polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol 21:1382- 1383, 2010
12. Rudin CM, Liu W, Desai A, et al: Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26:1119-1127, 2008
13. Aarnoudse AJ, Dieleman JP, Visser LE, et al: Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics 18:299-305, 2008
14. Fukui N, Suzuki Y, Sawamura K, et al: Dose-dependent effects of the 3435 CT genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit 29:185-189, 2007
15. Saitoh A, Sarles E, Capparelli E, et al: CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1- infected children. AIDS 21:2191-2199, 2007
16. Cascorbi I: Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457-473, 2006
17. van der Veldt AA, Eechoute K, Gelderblom H, et al: Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 17:620- 629, 2011
18. van Erp NP, Eechoute K, van der Veldt AA, et al: Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27:4406- 4412, 2009
19. Thiebaut F, Tsuruo T, Hamada H, et al: Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735-7738, 1987
20. Gotink KJ, Broxterman HJ, Labots M, et al: Lysosomal sequestration of sunitinib: A novel mechanism of drug resistance. Clin Cancer Res 17:7337-7346, 2011
21. Fabian MA, Biggs WH 3rd, Treiber DK, et al: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336, 2005